Target intelligence / Profile preview

Trypsin-3 (PRSS3)

Target
PRSS3
Molecular classification
Enzyme, Serine protease, Endopeptidase
01

Overview

Trypsin-3, also known as mesotrypsin and encoded by the PRSS3 gene, is one of three major human trypsin isoforms produced by the pancreas[5]. It is a serine protease enzyme responsible for the proteolytic cleavage of peptide bonds following lysine or arginine residues, primarily facilitating dietary protein digestion in the small intestine[8][5]. Unlike the more abundant trypsin-1 and trypsin-2, Trypsin-3 is notable for its resistance to common polypeptide trypsin inhibitors due to a unique structural modification (an arginine residue near its specificity pocket), allowing it to play a specialized role in degrading dietary and endogenous trypsin inhibitors that would otherwise impede protein digestion[5]. It is synthesized as an inactive zymogen (trypsinogen-3), secreted into the duodenum, and activated by enterokinase. Beyond its digestive function, Trypsin-3 can activate other digestive zymogens, participate in modulating inflammatory processes (notably via protease-activated receptors, especially PAR2), and has roles in metabolic regulation and disease pathogenesis, including possible involvement in pancreatic pathology, inflammation, and neurodegenerative diseases[4][5][8].

Other names
MesotrypsinPRSS3Serine protease 3Protease, serine 3
02

Mechanism of action

Proteolytic cleavage of peptide bonds after lysine or arginine - Inhibition by direct binding to active site (for inhibitors) - Drug inhibition by covalent or non-covalent binding to catalytic residues or substrate pocket

03

Biological functions

Protein digestionActivation of protease zymogens (such as chymotrypsinogen)Degradation of trypsin inhibitorsRegulation of proteolytic cascades
04

Disease associations

Pancreatic diseases (e.g., pancreatitis)Potential roles in cancer (limited evidence)InflammationNeurodegenerative disease (via PAR receptor activation)
05

Safety considerations

Systemic inhibition may impair protein digestionPancreatic self-digestion if prematurely activated (risk of pancreatitis)Off-target effects due to non-specificity of protease inhibitors
06

Interacting drugs

Trypsin inhibitors (e.g., Kazal-type inhibitors, Kunitz-type inhibitors)

2 more in the full profile.

07

Biomarkers

PRSS3 (Trypsin-3) expression as a marker of exocrine pancreatic functionTrypsin activity in serum or pancreatic juice (disease marker in pancreatitis)

Beyond the preview

Go deeper on Trypsin-3 (PRSS3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trypsin-3 (PRSS3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call